OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
| Autor: | Ramalingam, S.S., Ciuleanu, T.E., Pluzanski, A., Lee, J.-S., Schenker, M., Caro, R.B., Lee, K.H., Zurawski, B., Audigier-Valette, C., Provencio, M., Linardou, H., Kim, S.-W., Borghaei, H., Hellmann, M.D., O'Byrne, K.J., Paz-Ares, L.G., Reck, M., Nathan, F.E., Brahmer, J.R. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology January 2021 16(1) Supplement:S2-S3 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|